United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

18 Aug 2017
Change (% chg)

$0.10 (+0.46%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hindman, Andrew 

Mr. Andrew Hindman is Chief Business Development Officer of the Company. Prior to joining the Company, Mr. Hindman held several senior executive level positions in the biopharmaceutical industry, most recently from 2011 to 2014 as President, Chief Executive Officer and member of the Board of Tobira Therapeutics, a privately-held biotechnology company. At Tobira, Mr. Hindman was responsible for developing a new corporate strategy, building new leadership and operational teams, and raising operating capital. Prior thereto, Mr. Hindman held senior corporate development and commercial operating positions, including from 2010 to 2011 at Nodality, Inc., from 2008 to 2010 at Onyx Pharmaceuticals, Inc., and from 1998 to 2008 at Gilead Sciences, Inc. Mr. Hindman holds a B.A. in biochemistry and economics, graduating Phi Beta Kappa, from Wesleyan University and an executive MBA from Columbia University and the University of California Berkeley, Haas School of Business.

Basic Compensation

Total Annual Compensation, USD 699,876
Restricted Stock Awards, USD 408,027
Long-Term Incentive Plans, USD --
All Other, USD 696,578
Fiscal Year Total, USD 1,804,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen


Richard Batycky


David Lawrence


Andrew Blight


Jane Wasman


Burkhard Blank

As Of  30 Dec 2016